People with hepatitis C virus infection whose previous treatment with direct-acting antivirals (DAAs) failed are having success with a fixed-dose combination therapy of sofosbuvir, velpatasvir, and voxilaprevir (Vosevi, Gilead), according to the results a new study.
The 3 drugs included in the therapy target the NS5B polymerase (sofosbuvir), the NS5A protein (velpatasvir), and the NS3/4A protease (voxilaprevir). For the study, investigators set out to determine whether the presence of resistance-associated substitutions (RASs) in DAA-experienced patients would inhibit the efficacy of the SOF/VEL/VOX therapy.
Of the 248 people enrolled in the study with NS5A experience, 82.7% had baseline NS5A or NS3 RASs. The majority (79%) had NS5A RASs. Study results revealed, however, that sustained virologic response after 12 weeks on SOF/VEL/VOX occurred regardless of the presence of NS5A or NS3 RASs, and regardless of the presence of RASs related to velpatasvir or voxilaprevir.